Revaprazan Hydrochloride

Revaprazan Hydrochloride (CAS No.: 178307-42-1) is a synthetic small molecule classified as a reversible potassium competitive acid blocker and proton pump modulator that is broadly used as a pharmacological tool in gastrointestinal biology, infection associated inflammation research, and early stage drug discovery workflows focused on acid secretion pathways. In mechanistic studies, it is characterized by reversible inhibition of gastric H plus K plus ATPase through interaction with the potassium binding region of the proton pump, leading to sustained suppression of acid secretory activity in experimental systems, and published cellular evidence further indicates modulation of inflammation linked signaling through attenuation of IkappaB alpha degradation and prevention of Akt inactivation, with downstream reduction of Helicobacter pylori induced COX 2 expression. Consistent with its functional class, reported in vitro potency is generally described within the nanomolar to micromolar range depending on assay format, species background, and endpoint selection, while cross platform profiling commonly evaluates acid related transporter activity, epithelial stress responses, and inflammatory mediator expression rather than relying on a single parameter. Typical research applications include use in gastric epithelial cell models, Helicobacter pylori associated mucosal injury paradigms, and preclinical animal studies of acid secretion and mucosal protection, as well as comparator use in screening campaigns for next generation proton pump and P CAB directed compounds; the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.